The Multiple Sclerosis (MS) market has become fiercely competitive with the introduction of new disease-modifying therapies (DMTs) over the past several years and new therapies, such as Roche’s ocrelizumab, on the horizon. As physicians, patients and industry adapt to these changes, Spherix Global Insights examines the most sought after market, first line new patient starts, in RealWorld Dynamix™: DMT New Starts in MS.
RealWorld Dynamix: DMT New Starts includes a robust patient chart review conducted with 242 US neurologists highlighting the most recent new start patients in their practice. Patient demographics, DMT treatment history, EDSS scores, lesion load, co-morbidities and QOL metrics are captured along with the drivers behind the brand choices when starting DMT treatment. In addition to the clinical and non-clinical patient presentations, neurologists provide information about their next step in the treatment algorithm.
About Spherix Global Insights
Spherix Global Insights is a business intelligence and market research company, specializing in renal, autoimmune, neurologic and rare disease markets. Our aim is to apply our commercial experience and unique relationships within core specialty markets to translate data into insight, enabling our clients to make smarter business decisions.
For more information contact:
Telephone: (800) 661-0571
Email: info@spherixglobalinsights.com
www.spherixglobalinsights.com
